What is ABBV's market cap?

$521B, based on the Nov 4 close of $294.83.

What is ABBV's P/E ratio?

50.4× trailing-twelve-month earnings of $10.33B.

Does ABBVIE pay a dividend?

Yes. The latest regular dividend was $1.73 per share (ex-date Oct 15), an annualised yield of 2.35%.

How much of ABBV is sold short?

15.6M shares, 0.9% of float, as of Oct 15, 2026.

What sector is ABBV in?

Healthcare, in the Pharmaceuticals industry.

NYSE · ABBVHealthcarePharmaceuticals

ABBVIE INC. (ABBV)

$294.83+3.09%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$288.52▲ 36.12% in range

Nov 3, 2025Low $197.38 · High $294.89Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

ABBVIE closed at $294.83 on Nov 4, up 3.09% — matching its 52-week closing high. Volume of 8.4M shares was 1.56× its 20-day average (above normal).

Split-adjusted performance: +10.6% over one month, +43.8% over six months, +39.1% over one year.

In the quarter ended Sep 30, 2026, revenue was $17.40B, up 10.3% from a year earlier, with a net margin of 24.2%.

Short interest was 15.6M shares at the Oct 15 settlement, down 4.3% from the prior report (0.9% of float, 2.7 days to cover).

After its Oct 30 report (EPS beat estimates by 2.4%), the stock moved -0.7% from the close before to the close after.

Market cap$521.00B1.77B shares

Revenue · quarter$17.40B+10.3% YoY

Diluted EPS$2.37+2270.0% YoY

P/E · TTM50.4×P/S 7.9×

Net margin24.2%Gross 75.4%

Dividend yield2.35%$1.73 last paid

52-week range197.38 – 294.890.0% from high

Volume8.4M1.56× 20-day avg

Volatility · 60d21.1%Annualised

Short % of float0.9%2.7 days to cover

Net cash-$70.13BCash $10.77B

Next earnings—Not scheduled

Split-adjusted performance

1W +3.1%1M +10.6%3M +20.9%6M +43.8%YTD +29.0%1Y +39.1%3Y +107.8%5Y +172.0%

Earnings reactions

History →

Oct 30−0.7%

Jul 31−4.8%

Apr 29+6.9%

Feb 4−2.9%

Close before the report to close after it.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum91

Revenue growth56

Net margin87

Value (low P/E)21

Size100

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short15.6M−4.3% vs prior

Days to cover2.7Settled Oct 15

% of float0.9%

Short vol. 10d26.6%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ABBVABBVIE	$294.83	+3.09%	+43.8%	+10.3%	24.2%	50.4	$521.00B
JNJJohnson & Johnson	$276.32	+3.81%	+23.0%	+5.9%	0.8%	41.3	$665.19B	Compare
MRKMerck & Co.	$150.36	+3.93%	+32.4%	+5.1%	−8.0%	116.9	$370.96B	Compare
LLYEli Lilly &	$1,417.99	+0.61%	+43.7%	+38.6%	26.4%	45.8	$1.26T	Compare
ABTAbbott Laboratories	$115.51	+5.58%	+33.8%	+13.0%	7.4%	36.8	$199.88B	Compare
PFEPfizer	$30.79	+2.63%	+16.1%	+2.6%	−1.6%	40.5	$175.49B	Compare
VRTXVertex Pharmaceuticals	$549.04	+3.44%	+28.4%	+11.8%	19.0%	35.0	$139.16B	Compare
BMYBristol-Myers Squibb	$64.19	+4.02%	+13.4%	+5.7%	25.6%	14.1	$131.21B	Compare
REGNRegeneron Pharmaceuticals	$930.67	−4.39%	+29.1%	+36.3%	38.1%	20.0	$96.28B	Compare

News about ABBVIE

All news →

Quick answers

What does ABBVIE do?: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.
What is ABBV's market cap?: $521B, based on the Nov 4 close of $294.83.
What is ABBV's P/E ratio?: 50.4× trailing-twelve-month earnings of $10.33B.
Does ABBVIE pay a dividend?: Yes. The latest regular dividend was $1.73 per share (ex-date Oct 15), an annualised yield of 2.35%.
How much of ABBV is sold short?: 15.6M shares, 0.9% of float, as of Oct 15, 2026.
What sector is ABBV in?: Healthcare, in the Pharmaceuticals industry.

About ABBVIE

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.

HQ: North Chicago, IL57,000 employeesListed Dec 10, 2012abbvie.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology